Basf Aktiengesellschaft

Knoll Aktiengesellschaft

Abbott Laboratories Corporation

Abbvie Inc.

Abbott Gmbh & Co Kg

Knoll Atkiengesellschaft

Abbvie Deutschland Gmbh and Co Kg

Joerg Rosenberg

Jorg Breitenbach

Joerg Breitenbach

Axel Sanner

Gunther Berndl

Werner Maier

Laman L Alani

Bernd Liepold

Soumojeet Ghosh

J&ouml;rg Breitenbach

Sven Grabowski

Ulrich Reinhold

Hans-Heinrich Gruenhagen

Cynthia A Romerdahl

Andreas Kleinke

Helmut Fricke

Matthias Degenhardt

Juergen Heberger

Thomas Kessler

Hans D Zettler

Christoph Schmidt

Michael Schiessl

J&uuml;rgen Zeidler

Harald Krull

Katja Fastnacht

Dieter Lenke

Geoff G Z Zhang

Yi Gao

Gerda Von Philipsborn

Russell Drew Cink

Jurgen Hofmann

Stephan Kothrade

Jens Rieger

Rudolf Binder

John B Morris

Markus Maegerlein

Harald Hach

Norbert Steiger

J&ouml;rg Neumann

Egon Brode

Joseph B Paterson, Jr

Winfried Mueller

Axel Paul Hartl

Rolf Neidhardt

Guenter Blaich

Michelle A Long

Jurgen Zeidler

Tina Jung

Wolfgang Roth

Yan Cai

Cheri E Klein

A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50&#xb0; C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

Solid pharmaceutical dosage form

The invention relates to stable solid dosage forms for peroral administration containing, in addition to an ubiquinone, at least one thermoplastically processible matrix-forming auxiliary agent.

Stable dosage forms containing ubiquinones

In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.

Salts of fenofibric acid and pharmaceutical formulations thereof

A solid or semisolid, at least two-phase active ingredient-containing formulation in which there is multiparticulate incorporation of one of the two phases into a matrix of the other phase, and at least one of the phases contains at least one active ingredient, obtainable by introducing particles of one phase into the other phase in a plastic state, and shaping the material while still plastic.

Multiphase active ingredient-containing formulations

Lipids are used as aids in the production of solid drug forms by melt extrusion.

Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process

Slow-release matrix pellets and the production thereof

Preparations of non-steroidal analgesics

A process for producing solid dose forms by mixing at least one polymeric binder, with or without at least one active ingredient and with or without conventional additives, and shaping the mixture, where at least one of the components is employed in liquid form.

Process for producing solid dosage forms by extrusion

Solid medicaments obtained by extrusion of an isomalt-containing polymer-active substance melt

Production of lenticular tablets by melt calendering

Method of producing multi-layer medicaments in solid form for oral or

Growing community of inventors

Ellerstadt, Germany

Joerg Rosenberg